aXichem AB
AXIC-A.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$130.72M
Close$
Share Statistics
| Market cap | $130.72 Million |
|---|---|
| Enterprise Value | $128.44 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.3 |
| Beta | -0.69 |
| Outstanding Shares | 67,729,121 |
Return
| Return on Equity | -28.08% |
|---|---|
| Return on Assets | -26.09% |
| Return on Invested Capital | -27.63% |
Valuation & Multiples
| P/E Ratio | -7.75 |
|---|---|
| PEG | -30.33 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 7.9 |
| Enterprise Value to EBIT | -8.41 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$5.44 M
Average shareholder expectationNext Earnings Call
Expected Date
November 26, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
$7.57 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About aXichem AB
7 employees
CEO: Torsten Helsing aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary h...